Your browser doesn't support javascript.
loading
ADVANCE system testing: Can coverage of pertussis vaccination be estimated in European countries using electronic healthcare databases: An example.
Emborg, Hanne-Dorthe; Kahlert, Johnny; Braeye, Toon; Bauwens, Jorgen; Bollaerts, Kaatje; Danieli, Giorgia; Duarte-Salles, Talita; Glismann, Steffen; Huerta-Alvarez, Consuelo; de Lusignan, Simon; Martín-Merino, Elisa; McGee, Chris; Correa, Ana; Tramontan, Lara; Weibel, Daniel; Sturkenboom, Miriam.
Afiliação
  • Emborg HD; Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen, Denmark. Electronic address: hde@ssi.dk.
  • Kahlert J; Aarhus University Hospital, Olof Palmes Alle 43-45, DK-8200 Aarhus, Denmark. Electronic address: jok@clin.au.dk.
  • Braeye T; Sciensano, Rue Juliette Wytsmanstraat 14, 1050 Brussels, Belgium. Electronic address: toon.braeye@sciensano.be.
  • Bauwens J; University Children's Hospital Basel, PO Box, CH 4033 Basel, Switzerland; University of Basel, Switzerland; Brighton Collaboration Foundation, Switzerland. Electronic address: j.bauwens@brightoncollaboration.org.
  • Bollaerts K; P-95 Epidemiology and Pharmacovigilance, Leuven, Belgium. Electronic address: kaatje.bollaerts@p-95.com.
  • Danieli G; Consorzio Arsenàl.IT, Veneto Region, Italy; PEDIANET, Padova, Italy. Electronic address: gdanieli@consorzioarsenal.it.
  • Duarte-Salles T; Fundació Intitut Universitari per a la recerca a I'Atenció Primària de Salut Jordi Gol I Gurina (IDIAPJGol), Barcelona, Spain. Electronic address: tduarte@idiapjgol.org.
  • Glismann S; GSK, Av. Fleming 20, 1300 Wavre, Belgium. Electronic address: steffen.x.glismann@gsk.com.
  • Huerta-Alvarez C; BIFAP Database, Spanish Agency of Medicines and Medical Devices, Madrid, Spain. Electronic address: chuerta@aemps.es.
  • de Lusignan S; University of Surrey, Guildford, Surrey GU2 7XH, UK; Royal College of General Practitioners Research and Surveillance Centre, 30 Euston Square, London NW1 2FB, UK. Electronic address: simon.delusignan@phc.ox.ac.uk.
  • Martín-Merino E; BIFAP Database, Spanish Agency of Medicines and Medical Devices, Madrid, Spain. Electronic address: emartinm@aemps.es.
  • McGee C; University of Surrey, Guildford, Surrey GU2 7XH, UK; Royal College of General Practitioners Research and Surveillance Centre, 30 Euston Square, London NW1 2FB, UK. Electronic address: c.mcgee@surrey.ac.uk.
  • Correa A; University of Surrey, Guildford, Surrey GU2 7XH, UK. Electronic address: accorrea1@googlemail.com.
  • Tramontan L; Consorzio Arsenàl.IT, Veneto Region, Italy; PEDIANET, Padova, Italy. Electronic address: ltramontan@consorzioarsenal.it.
  • Weibel D; Erasmus University Medical Center, PO Box 2014, 3000 CA Rotterdam, the Netherlands; VACCINE.GRID Foundation, Spitalstrasse 33, Basel, Switzerland. Electronic address: daniel@weibelconsult.com.
  • Sturkenboom M; P-95 Epidemiology and Pharmacovigilance, Leuven, Belgium; VACCINE.GRID Foundation, Spitalstrasse 33, Basel, Switzerland; Julius Global Health, Julius Center, University Medical Center Utrecht, Heidelberglaan 100, the Netherlands. Electronic address: m.c.j.sturkenboom@umcutrecht.nl.
Vaccine ; 38 Suppl 2: B22-B30, 2020 12 22.
Article em En | MEDLINE | ID: mdl-31677953
INTRODUCTION: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test a system for rapid benefit-risk (B/R) monitoring of vaccines, using existing healthcare databases in Europe. The objective of this paper was to assess the feasibility of using electronic healthcare databases to estimate dose-specific acellular pertussis (aP) and whole cell pertussis (wP) vaccine coverage. METHODS: Seven electronic healthcare databases in four European countries (Denmark (n = 2), UK (n = 2), Spain (n = 2) and Italy (n = 1)) participated in this study. Children were included from birth and followed up to age six years. Vaccination exposure was obtained from the databases and classified by type (aP or wP), and dose 1, 2 or 3. Coverage was estimated using period prevalence. For the 2006 birth cohort, two estimation methods for pertussis vaccine coverage, period prevalence and cumulative incidence were compared for each database. RESULTS: The majority of the 2,575,576 children included had been vaccinated at the country-specific recommended ages. Overall, the estimated dose 3 coverage was 88-97% in Denmark (birth cohorts from 2003 to 2014), 96-100% in the UK (2003-2014), 95-98% in Spain (2004-2014) and 94% in Italy (2006-2007). The estimated dose 3 coverage per birth cohort in Denmark and the UK differed by 1-6% compared with national estimates, with our estimates mostly higher. The estimated dose 3 coverage in Spain differed by 0-2% with no consistent over- or underestimation. In Italy, the estimates were 3% lower compared with the national estimates. Except for Italy, for which the two coverage estimation methods generated the same results, the estimated cumulative incidence coverages were consistently 1-10% lower than period prevalence estimates. CONCLUSION: This study showed that it was possible to provide consistent estimates of pertussis immunisation coverage from the electronic healthcare databases included, and that the estimates were comparable with the national estimates.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina contra Coqueluche / Coqueluche Tipo de estudo: Risk_factors_studies Limite: Child / Humans País/Região como assunto: Europa Idioma: En Revista: Vaccine Ano de publicação: 2020 Tipo de documento: Article País de publicação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacina contra Coqueluche / Coqueluche Tipo de estudo: Risk_factors_studies Limite: Child / Humans País/Região como assunto: Europa Idioma: En Revista: Vaccine Ano de publicação: 2020 Tipo de documento: Article País de publicação: Holanda